Symbicort study provides insight into asthma treatment for African-Americans
This article was originally published in Scrip
Executive Summary
New results from a long-term study of AstraZeneca's Symbicort (budesonide/ formoterol fumarate dihydrate) showed that the drug significantly improved the lung function of African-American patients with moderate-to-severe persistent asthma.